Gastroduodenal Ulcer
Conditions
Brief summary
An Open-Label, Randomized, Two-sequence, Two-period, Fasting Condition, Single Oral Dose, Cross-over Study of Bioequivalence of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer) and Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug) in Healthy, Adult, Human Subjects.
Detailed description
1. Study design: An open-Label, randomized, two-sequence, two-period, fasting condition, single oral dose, cross-over study 2. Administration method: The subject should maintain a minimum of 10 hours of empty stomach before administration, and swallow an oral dose of 1 tablets (Famotidine 20 mg) after moistening mouth with 20 mL of water and dissolving completely with saliva on the tongue without water at around 8 a.m. on the day of the test at room temperature. The subject should not chew the drug or break it, but should swallow in whole with water. The difference in administration time between the test subjects is about one minute apart, considering the collection time. 3. Wash out period: 7 days 4. Blood collection time: Before the administration, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 hr after the administration (total 13 times) 5. Analysis: Measurement of the concentration of an unchangeable substance of Famotidine in plasma
Interventions
DRUGIGAD→GSTD
Drug: IGAD First Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug) Other: Washout period 7 days Drug: GSTD Second Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)
DRUGGSTD→IGAD
Drug: GSTD First Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer) Other: Washout period 7 days Drug: IGAD Second Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)
Sponsors
Dong-A ST Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. A person who aged 19 or older at the time of screening 2. No congenital or chronic diseases or pathological symptoms on screening 3. A person who is judged to be suitable for the study by the investigator based on the clinical laboratory examination 4. BMI of 18 to 30 (BMI calculation: kg/m2) 5. No history of gastrointestinal resection that may affect the absorption of drugs 6. No medical history of mental illness within five years prior to screening 7. A person who has fully understood the contents of the consent form for the study and signed the consent form voluntarily and recorded the date of signature 8. A person who is willing and able to follow all scheduled hospitalization and outpatient visits, medications, clinical laboratory examination and the terms of compliance 9. Female patients who were confirmed to be not pregnant at medical examination
Exclusion criteria
1. A person who has taken a drug that significantly induces (e.g., barbital) or inhibits the drug metabolic enzyme within 30 days prior to first administration of the IP 2. A person who uses drugs that can affect the study within 10 days before first administration of the IP 3. A person who is considered unsuitable to participate in the study by the investigator 4. A person who has participated in other clinical trials within 6 months prior to the first administration of the IP 5. A person who has had whole blood transfusion within 2 months or the apheresis within 2 weeks before first administration of IP 6. A person who is hypersensitive to venipuncture 7. A person with a history of regular alcohol intake within six months prior to screening: * Women: More than 14 glasses/week * Men: More than 21 glasses/week (1 shot: 50 ml of soju, 30 ml of spirits, 250 ml of beer) 8. Blood AST (GOT) or ALT (GPT) levels exceed the upper reference range limit by 2 times or γ-GTP levels exceed the upper reference range limit by 1.5 times 9. Hypersensitive to any of the IP components 10. Patient with hereditary disease Phenylketonuria who need to regulate their intake of phenylalanine 11. Lactating women 12. A person who does not agree to exclude the possibility of pregnancy using the contraception from the date of the first administration of the IP until the 7th day after the last administration.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUClast | Before administration ~ 24hr | Area Under the plasma Concentration versus time curve(AUClast) of Famotidine |
| Cmax | Before administration ~ 24hr | Peak Plasma Concentration(Cmax) of Famotidine |
Contacts
Primary ContactSeungHyun Kang, Ph.D
Outcome results
None listed